Hormonal
Anti-inflammatory interventions (including omega-3 fatty acids, exercise, and cytokine antagonists) significantly improve mood and reduce depressive symptoms, but only in individuals with pre-existing heightened inflammation (e.g., high CRP or IL-6 levels).
If you have depression, ask your doctor about testing inflammatory markers like CRP or IL-6. If these are high, treatments like omega-3 supplements (specifically EPA), exercise, or anti-inflammatory medications might be more effective for you than standard antidepressants alone. If your inflammation is low, these treatments may not help, and you should focus on other therapeutic strategies.
a theme across research with cytokine antagonists, omega-3 fatty acids, celecoxib, and exercise is that anti-inflammatory interventions have a substantially greater impact on mood in individuals with heightened inflammation.
Why this rating
Supported by multiple meta-analyses, prospective cohort studies, and randomized controlled trials (e.g., infliximab, omega-3s, exercise) showing dose-response relationships between inflammation levels and treatment response.
Source
Inflammation: Depression Fans the Flames and Feasts on the Heat
Janice K. Kiecolt‐Glaser et al. · American Journal of Psychiatry · 2015
DOI 10.1176/appi.ajp.2015.15020152
More from this paper
- Depression and inflammation form a bidirectional, self-reinforcing loop where depression primes exaggerated inflammatory responses to stressors, and inflammation promotes depressive symptoms via sickness behaviors and neurobiological changes.Strong
- Lifestyle factors including Mediterranean-style diet, caloric restriction/fasting, and exercise reduce systemic inflammation (CRP, IL-6) and can mitigate the risk of developing depression, particularly in those with existing depressive symptoms.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →